Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

42 results about "Hiv infected" patented technology

Causes of HIV infection. The human immunodeficiency virus (HIV) is a virus transmitted by body fluids. Contact with blood, semen, vaginal fluid, rectal fluids, and breast milk from an infected person can cause infection. In the U.S., HIV infection is usually spread through sexual activity or by sharing needles or syringes.

Primer probe combination and kit for HIV-1 (human immunodeficiency virus-1) nucleic acid detection

The invention relates to the field of biological detection, in particular to a primer probe combination and a kit for HIV-1 (human immunodeficiency virus-1) nucleic acid detection. The primer combination provided by the invention comprises a primer group I and / or a primer group II, the primer group I has a nucleotide sequence as shown in any of SEQ ID NO: 1 to SEQ ID NO: 4; the primer group II has a nucleotide sequence as shown in any of SEQ ID NO: 5 to SEQ ID NO: 8. The kit provided by the invention can be stored for 1 year at 2-8 DEG C, and has good stability. Meanwhile, the detection method and the kit provided by the invention have the advantages of strong specificity, high sensitivity, simplicity and convenience in operation, clear result, high reliability and wide coverage. The invention has potential application prospects in detection and identification of HIV-1 and auxiliary diagnosis of HIV infected persons, and has great influence on prevention and treatment of AIDS and public health.
Owner:AUTOBIO DIAGNOSTICS CO LTD

Application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (Human Immunodeficiency Virus) combined hyperlipidemia

The invention belongs to the field of biomedicine, and particularly relates to application of ABCG1 in diagnosis or auxiliary diagnosis of HIV (human immunodeficiency virus) combined hyperlipidemia. Through detection, the expression of the ABCG1 in the blood of a patient with HIV combined with hyperlipidemia is obviously reduced, the ABCG1 is verified to have the characteristics of high sensitivity and high specificity, whether hyperlipidemia exists in an HIV infected group or not can be diagnosed or diagnosed in an auxiliary manner by detecting the expression of the ABCG1, guidance is provided for early intervention of hyperlipidemia in the HIV infected group, and the method is suitable for clinical application. Wide clinical application prospects are realized.
Owner:核工业四一六医院

Application of CD4+CD8 + double-positive T cell in improvement of poor immune reconstruction of HIV infected patient

The invention discloses an application of CD4 + CD8 + double-positive T cells in improvement of poor immune reconstitution of HIV (human immunodeficiency virus) infected patients, and relates to the technical field of biological pharmacy, in particular to the application of preparation of the CD4 + CD8 + double-positive T cells in the poor immune reconstitution of the HIV infected patients. The number of peripheral blood CD4 + T cells of HIV infected patients is increased, the immune system of the patients is improved, and the probability of possible opportunity infection and other related diseases of the patients is reduced, so that the morbidity and mortality of the patients are reduced.
Owner:FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV

Application of metabolite in prediction of immune reconstruction result after anti-retrovirus treatment of HIV infected person

ActiveCN119028455AEffectively predict immune reconstitution outcomesComponent separationBiostatisticsMetabolomeHiv infected
The invention discloses a metabolite composition and an application thereof in prediction of an immune reconstruction result after anti-retrovirus treatment of an HIV (Human Immunodeficiency Virus) infected person. According to the present invention, the metabolite combination and the model capable of accurately distinguishing the immune responder from the immune non-responder are firstly found, the metabolite combination and the model are respectively Glycylcycloyproline, gamma-Glutamylalanine, C16-Sphingosine-1-phosphate, didyroracil, deoxyeritadenine, creatinine, trans-S-(1-Propenyl)-L-cysteine, N6, N6, N6-Trimetyl-L-lyine and glucosamine, the content of the metabolite combination of the subject is detected so as to distinguish whether the subject can recover the optimal immunity after the subject is subjected to the anti-retrovirus treatment, and whether the subject can recover the optimal immunity after the subject is subjected to the anti-retrovirus treatment can Therefore, the treatment process of the HIV infected person is better intervened, and the treatment scheme of the HIV infected person is guided and optimized according to the treatment reaction.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Computer device and computer readable storage medium for evaluating post-ART immune reconstruction state of HIV infected person

The invention discloses a computer device and a computer readable storage medium for evaluating the immune reconstitution state of an HIV infected person after ART. Belongs to the field of computer information. The technical problem to be solved by the invention is how to evaluate the immune reconstruction state of an HIV infected person after ART. The invention provides a computer program stored in a memory in a computer device. The computer program comprises the following steps: S1, receiving sample data, namely the proportion of the number of cells expressing PD-1 in CD8 + T cells of peripheral blood mononuclear cells of an HIV infected subject after ART and the proportion of the number of cells expressing at least one of the following five factors: CD38, HLA-DR, CD57, PERFORIN and CD107A; s2, obtaining a predicted value Y from the sample data through a model formula, and outputting an immune reconstruction condition according to the predicted value Y and a pre-judgment condition; the method can accurately and efficiently determine whether the immune reconstruction state of the HIV infected person subjected to antiviral treatment is good or not.
Owner:BEIJING YOUAN HOSPITAL CAPITAL MEDICAL UNIV

Gene sequence construct for gene therapy for HIV infection

The present invention relates to a gene sequence construct for gene therapy for HIV infection. The gene sequence construct is constructed by means of sequentially connecting, via a coding sequence of a linker polypeptide, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody against antigens at different binding sites involved in the different steps of HIV infection of a human CD4+ T cell, a gene coding sequence of a variable region scFv in each light chain and heavy chain of a monoclonal antibody bound to a human CD4 receptor site, a gene coding sequence of an Fc fragment in a human IgG constant region, and a gene coding sequence of a polypeptide for inhibiting the fusion of HIV and a CD4+ T cell membrane, and by placing the connected gene coding sequences downstream of a promoter and a secretion signal peptide coding sequence, thereby expressing a single-gene-encoded secretion-type antibody-like protein molecule. The recombinant single-gene construct can be conveniently introduced into a target tissue cell via a viral vector, and the expressed secretion-type antibody-like protein molecule has multi-antigen tropism, can realize the efficient and broad-spectrum blockade of the HIV infection process on a human CD4+ T cell by means of binding to multiple binding sites involved in the different steps of HIV infection of the human CD4+ T cell, and effectively avoids the loss of the ability to inhibit an HIV infection due to an HIV escape mutation, thereby achieving a long-term or even permanent treatment effect on HIV infection by means of a single injection.
Owner:KANGLIN BIOTECHNOLOGY (HANGZHOU) CO LTD

Application of lipid in prediction of immune reconstruction result after anti-retrovirus treatment of HIV infected person

PendingCN118983095AIntervention in the treatment processOptimize treatment planMedical data miningComponent separationLipidomeDisease
The invention discloses a lipid composition and application thereof in constructing a model for predicting an immune reconstruction result of an HIV infected person after anti-retrovirus treatment. According to the present invention, the lipid combination capable of accurately distinguishing the immune responder from the immune non-responder is firstly found, the lipid combination comprises LPC16: 1, LPC16: 0, FFA20: 4, PE38: 7 (16: 122: 6), GM3d18: 1 / 22: 0, TAG53: 3 (19: 1), TAG54: 7 (22: 6) and TAG56: 7 (22: 6), and whether the subject is the immune non-responder can be distinguished by detecting the content of the lipid combination of the subject and constructing the model, such that the disease progress after the HIV infected person is subjected to the anti-retrovirus treatment can be well intervened, and the anti-retrovirus treatment can be easily performed. And the treatment scheme of the HIV infected person is guided and optimized according to the treatment reaction.
Owner:THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL

Chimeric antigen receptor targeting HIV infected cells, CAR-T cell and application

The invention discloses a chimeric antigen receptor targeting an HIV infected cell, a CAR-T cell and application. The chimeric antigen receptor comprises an antigen binding domain, a chimeric receptor hinge region, a transmembrane domain, a costimulatory signal transduction domain and a signal transduction domain, the antigen binding structural domain is an anti-HIV monoclonal antibody JSR771 and is composed of a heavy chain VH and a light chain VL, the amino acid sequence of the heavy chain VH is as shown in SEQ ID NO.1, and the amino acid sequence of the light chain VL is as shown in SEQ ID NO.2. The invention further discloses a preparation method of the anti-HIV monoclonal antibody JSR771. By optimizing the separation, activation, transduction and culture conditions of the T cells and strictly controlling the quality control standard, the prepared anti-HIV-1CAR-T cells have high motility, high specificity and strong killing ability, and a new hope is provided for clinical treatment of HIV infection.
Owner:THE THIRD PEOPLES HOSPITAL OF SHENZHEN

Intelligent decision support system for antiviral treatment of newly diagnosed HIV infected person

The invention belongs to the technical field of medical information, and particularly relates to a newly diagnosed HIV infected person antiviral treatment intelligent decision support system which comprises a multi-source data integration module, a medicine knowledge module, an individualized decision support module, an interactive output module, a knowledge optimization module and a safety and privacy protection module. The system replaces doctors to query and integrate patient data across multiple systems, clinical time is saved, key information omission is avoided, comprehensive data support is provided for treatment decisions, experience decisions are converted into systematic analysis and graded risk prompts are generated by means of an individualized decision support module, scheme deviation is effectively reduced, the medication risk is reduced, and the treatment efficiency is improved. The method assists the basic level in improving the treatment normalization, allows doctors to input new experience and new achievements summarized in practice into the system after double-blind auditing, and provides continuously iterative knowledge support for the scientificity of the antiviral treatment decision of the newly diagnosed HIV infected person.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV

Methods and materials for killing HIV infected cells

InactiveEP4461314A3Peptide/protein ingredientsAntiviralsCd4 t cellHiv infected
This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Human immunodeficiency virus-specific T cell receptors

Engineered TCR molecules specific to retroviral peptide / HLA complexes guide direct killing and / or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (Vα) domain, a TCR variable beta domain (Vβ) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.
Owner:ALTOR BIOSCIENCE LLC +1

Method of treatment of HIV infection with vaccine

The present disclosure relates to methods for determining the magnitude of a subject's immune response against a HIVACAT T-cell immunogen (HTI or “HTI immunogen”) and whether the subject can avoid antiretroviral therapy (ART). These methods are helpful for treating human immunodeficiency virus (HIV) and / or deciding whether to administer, continue or stop antiretroviral therapy in a subject. The present disclosure also relates to antigens, compositions, and kits related to such methods.
Owner:AELIX THERAPEUTICS SL +1

Tetrahydroquinazoline derivatives as selective cytotoxic agents

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Owner:MERCK SHARP & DOHME LLC

Benzoxazinone derivatives as selective cytotoxic agents

The present disclosure is directed to benzoxazinone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Owner:MERCK SHARP & DOHME LLC

Methods for treatment and prophylaxis of HIV and aids

The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and / or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula Ior a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
Owner:MERCK SHARP & DOHME LLC

Anti-HIV broad-spectrum neutralizing antibody with ADCC effect and application thereof

The invention relates to an anti-HIV broad-spectrum neutralizing antibody with an ADCC effect and application of the anti-HIV broad-spectrum neutralizing antibody in treatment and / or prevention of HIV infected diseases. The antibody FD22 disclosed by the invention shows broad-spectrum and strong neutralizing capacity on different subtype HIV-1 pseudoviruses which are prevalent globally, and particularly shows excellent neutralizing activity on HIV-1AE and BC subtype strains which are prevalent widely in China. The antibody FD22 is an effective supplement for the existing HIV neutralizing antibody drug library, and can provide more comprehensive prevention and treatment choices for Chinese epidemic strains. Meanwhile, the antibody FD22 can promote expression of NK cell activating factors, activate NK cells and improve the degranulation effect of the NK cells, so that the killing effect of immune cells such as the NK cells on HIV infected cells is enhanced, and the potential of treating HIV infection is shown.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY

HIV infection blocking combination and method based on CD2 signaling pathway

The present invention relates to compositions and methods for blocking viral replication (such as HIV-1 infection) using CD2 receptors. In one embodiment, viral target cells such as blood CD4 T cells can be made resistant to HIV by stimulating CD2 receptors using antibodies, ligands, or small molecules that bind to CD2 receptors. Pre-stimulation of CD2 can be used to enhance anti-HIV immunity and can be used to promote immune responses to HIV infection or anti-HIV vaccines.
Owner:吴云涛 +1

Combination therapies for HIV infections and uses thereof

The disclosure relates to therapeutic methods or methods of treating, clearing, preventing or curing Human Immunodeficiency Virus (HIV) infection. The disclosure provides a combination of at least one agent selected from the group consisting of: fostemsavir and temsavir, or a pharmaceutically acceptable salt thereof and a CD4 binding site (CD4bs) binding protein for the use in treatment of HIV and / or clearance of HIV infected cells.
Owner:VIIV HEALTHCARE CO

Application of gall gall lactone A in preparation of medicine for treating human immunodeficiency virus infectious diseases

The invention discloses application of brusatrolactone A in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicine. The invention provides an application of gall gall lactone A in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection disease, and the pharmaceutical composition comprises the brusatrolactone A and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the brusatrolactone A has a remarkable effect on inhibiting HIV (human immunodeficiency virus) from invading cells and inhibiting the replication of the HIV in host cells. The medicament not only expands the medicament selection of HIV infection, but also further expands the application range of the brusatrolactone A.
Owner:SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION (SHENZHEN HEALTH INSPECTION CENTER SHENZHEN INSTITUTE OF PREVENTIVE MEDICINE)

Application of micromolecule PRT4165 in preparation of anti-HIV latency drugs

The invention belongs to the field of medicines, and relates to an application of a small molecule drug in anti-HIV-1 latency. The invention provides an application of a micromolecule PTR4165 in preparation of an anti-HIV-1 latency drug. The anti-HIV-1 latency drug is a drug for promoting the transcription activation of a previrus in an HIV infected cell. The micromolecule PTR4165 can be combined with an HIV potential activator to be used as a pharmaceutical composition for promoting the transcription activation of a pre-virus in an HIV infected cell; the HIV potential activator comprises a histone deacetylase inhibitor SAHA, a BET inhibitor JQ1, a PKC agonist and a DNA methylation inhibitor 5-aza. The PTR4165 provided by the invention has a transcriptional activation effect on latent HIV in HIV infected cells no matter the PTR4165 is independently used or combined with a known activator, and can assist in deeper removal of HIV viruses.
Owner:FUDAN UNIV YIWU RES INST

Umbilical cord blood separation and pathogen detection integrated system

The invention discloses a cord blood separation and pathogen detection integrated system in the technical field of blood detection. The cord blood separation and pathogen detection integrated system comprises an information acquisition module, a data processing module, a separation module and a pathogen confirmation module, the information acquisition module is used for acquiring image information of umbilical cord blood cells; the data processing module analyzes the acquired image information through a trained deep learning model, judges whether the sample is HIV infection, HBV infection or non-infection, marks the sample which is judged to be HIV infection and HBV infection, and transmits the marked sample to the pathogen confirmation module; the separation module is used for centrifuging the umbilical cord blood sample and extracting stem cells; the pathogen confirmation module comprises a nucleic acid detection unit and an antigen-antibody detection unit, and the nucleic acid detection unit is used for automatically extracting cell nucleic acid and confirming whether the samples are infected or not according to the HIV infected and HBV infected samples marked by the data processing module; the antigen-antibody unit and a nucleic acid detection result are mutually verified through a chemical judge immunoassay method.
Owner:ZUNYI BEIKE RONGHUI LIFE TECH CO LTD

Method for realizing accurate follow-up visit for HIV infected person

PendingCN119673487APrevention and Control of Spreading EpidemicsGet it in timeMedical communicationMedical data miningInformation behaviourTransmissible disease
The invention belongs to the technical field of infectious disease monitoring, and more specifically relates to a method for realizing accurate follow-up visit for an HIV infected person. The method comprises the following steps: collecting basic data from a Chinese disease prevention and control information system, managing the basic data and importing the basic data into the information system; the diagnosis and treatment receiving service information, the sociology information, the behavioral information and the biological information of the HIV infected persons are synthesized, and grading standards are formulated for the HIV infected persons; querying the case information of the HIV infected person according to the information system query condition template, judging the grade of the case of the current HIV infected person belonging to the grading standard, and carrying out grading marking; respectively formulating corresponding intervention measures for infected persons of different grades; and the primary-level workers carry out accurate follow-up work on the HIV infected persons according to the grading marks and corresponding intervention measures. The problems that in the prior art, individual case information cannot be provided, the risk cannot be judged by integrating infected person information, and complexity, time consumption and low accuracy are solved.
Owner:SHANDONG CENT FOR DISEASE CONTROL & PREVENTION

Method for detecting infection with aids virus

The purpose of the present invention is to provide a method for detecting whether a subject is infected with AIDS virus (HIV) or is in a latent HIV infection state, or whether the subject is suspected of being infected with HIV or being in a latent HIV infection state. The present invention provides a method for determining whether a mammalian subject is infected with HIV or is in a latent HIV infection state, or whether the mammalian subject is suspected of being infected with HIV or being in a latent HIV infection state, the method involving: a step for detecting the amount of 3-methylcytidine (m3C) in a sample derived from the subject; and a step for providing information on the detected amount for the determination.
Owner:NAT UNIV CORP KUMAMOTO UNIV

Tetrahydroquinazoline derivatives as selective cytotoxic agents

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Owner:MERCK SHARP & DOHME LLC

Anti-aging traditional Chinese medicine composition as well as preparation method and application thereof

The invention belongs to the technical field of traditional Chinese medicines, and discloses an anti-aging traditional Chinese medicine composition as well as a preparation method and application thereof. The composition is prepared from 12-24 parts of fructus lycii, 12-24 parts of raspberry, 12-15 parts of emblic leafflower fruit, 24 parts of rhizoma polygonati, 12-24 parts of pulp of dogwood fruit, 6 parts of folium mori and 9 parts of rhodiola rosea. The traditional Chinese medicine composition is guided by the theory of traditional Chinese pharmacology, follows the anti-aging core of reinforcing kidney, strengthening spleen and stomach and regulating liver pivot, is combined with clinical practice to screen traditional Chinese medicines with anti-oxidation and anti-inflammatory effects, and can tonify deficiency and strengthen body resistance. Clinical research proves that after the composition intervenes the HIV infected person for 3 months, the composition can significantly reduce the early apoptosis rate of peripheral T cells, improve the Ki67 proliferation index of CD4 + T cells and CD8 + T cells, relieve immune depletion, have no abnormal blood routine and liver and kidney functions, can improve clinical symptoms such as insomnia and weakness, improve the energy level of the body, and provide a safe and effective scheme for premature senility intervention of the HIV infected person.
Owner:CHINESE ACAD OF PREVENTIVE MEDICINE

Application of gene marker for risk assessment of active tuberculosis of HIV infected person

The invention relates to the technical field of biomedicine, in particular to application of a gene marker for risk assessment of active tuberculosis of an HIV infected person. According to the application of the provided quantitative detection reagent of the gene marker in preparation of a product for evaluating the risk of the HIV infected person suffering from the active tuberculosis, the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2, and the gene marker shown as Seq.No1-6 comprises one or more of BEX5, CEL, DUSP14, EIF3I, PPFIA4 and TSEN2. According to the application, the problem of identifying active tuberculosis high-risk groups in HIV infected persons is solved from the gene level, the disease progress trend can be captured earlier and more accurately from the gene level, and a foundation is laid for targeted implementation of tuberculosis preventive treatment.
Owner:GUANGZHOU EIGHTH PEOPLES HOSPITAL GUANGZHOU MEDICAL UNIV

Peptide molecules for specific recognition of HIV gp120 protein and their applications

The application provides a polypeptide molecule for specifically recognizing HIV gp120 protein and an application thereof, and belongs to the technical field of biological medicine. The application provides a lead polypeptide derivative for specifically targeting and combining HIV gp120, wherein the lead polypeptide comprises an amino acid sequence shown in SEQ ID No. 1. The application also provides a lead polypeptide derivative prepared based on the lead polypeptide, and a polypeptide nanoparticle constructed by the lead polypeptide derivative, and both of them have gp120 protein combining capacity. The derivative and the nanoparticle have good virus neutralization inhibition effect. The series of polypeptide molecules can specifically combine with free HIV virus, HIV infected cells and free gp120, so as to block HIV infected cells, delay the AIDS disease process, realize AIDS treatment drug targeted delivery, detection and diagnosis.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Tetrahydroquinazoline derivatives as selective cytotoxic agents

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Owner:MERCK SHARP & DOHME LLC

Application of ipecine in preparation of medicine for treating human immunodeficiency virus infectious diseases

The invention discloses application of ipecine in preparation of a medicine for treating HIV infectious diseases, and belongs to the technical field of biological medicines. The invention provides an application of ipecine in preparation of a medicine for treating human immunodeficiency virus infectious diseases. The invention also relates to a pharmaceutical composition for treating the HIV infection diseases, and the pharmaceutical composition comprises ipecine and pharmaceutically acceptable auxiliary materials. A cell model experiment proves that the ipecine has a remarkable effect on inhibiting HIV (Human Immunodeficiency Virus) from invading cells and inhibiting the replication of the HIV in host cells. The drug not only expands the drug selection of HIV infection, but also further expands the application range of the ipecine.
Owner:SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION (SHENZHEN HEALTH INSPECTION CENTER SHENZHEN INSTITUTE OF PREVENTIVE MEDICINE)

Tetrahydroquinazoline derivatives as selective cytotoxic agents

The present disclosure is directed to tetrahydroquinazoline derivatives of Formula Iand their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
Owner:MERCK SHARP & DOHME LLC